Thermo Fisher to Pay $587M for Convertible Notes | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that its offer to purchase any and all outstanding 2.5 percent convertible senior notes due 2023 has expired, with 95.6 percent of the outstanding notes validly tendered.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.